Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863518 | 0.92 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30107533 | 0.91 | REN (0.41) | NMBRSIRT2 | |
| SCHEMBL30250367 | 0.90 | NMBR (0.42) | NMBRSIRT2 | |
| SCHEMBL30384193 | 0.89 | ACE (0.37) | NMBRSIRT2PSEN1PSEN2APH1B | |
| SCHEMBL30384919 | 0.88 | SIRT2 (0.44) | NMBRSIRT2 | |
| SCHEMBL30665993 | 0.86 | NMBR (0.44) | NMBRSIRT2 | |
| SCHEMBL30524340 | 0.85 | PSEN1 (0.37) | NMBRSIRT2PSEN1PSEN2APH1B | |
| SCHEMBL30343346 | 0.83 | PSEN1 (0.36) | NMBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL30277394 | 0.81 | NMBR (0.44) | NMBRSIRT2 | |
| SCHEMBL31414641 | 0.81 | NMBR (0.46) | NMBRSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133716-A1 | PREPARATION METHOD FOR SEMAGLUTIDE | Shenzhen JYMed Technology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133716-A1 | PREPARATION METHOD FOR SEMAGLUTIDE | GCG, GLP1R, DPP7 | NMBR 3029/4885SIRT2 2902/4885PSEN1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.